The New York Times
BREAKING NEWS
Novavax’s Covid-19 vaccine has proven highly effective in a new trial. But with the U.S. awash in other options, it might be needed more elsewhere.
Monday, June 14, 2021 6:00 AM EST
In the 29,960-person trial, the vaccine demonstrated an overall efficacy of 90.4 percent, on par with the vaccines made by Pfizer-BioNTech and Moderna, and higher than the one-shot vaccine from Johnson & Johnson. The Novavax vaccine showed an efficacy of 100 percent at preventing moderate or severe disease.
Do something positive.